We are live on ! Find out more
PCM

Peregrine Capital Management Portfolio holdings

AUM $3.08B
1-Year Est. Return 29.51%
This Fund
S&P 500
This Quarter Est. Return
+4.37%
1 Year Est. Return
+29.51%
3 Year Est. Return
+95.04%
5 Year Est. Return
+107.83%
10 Year Est. Return
+715.34%
AUM
$3.26B
AUM Growth
-$60.9M
Cap. Flow
-$92.3M
Cap. Flow %
-2.83%
Top 10 Hldgs %
25.7%
Holding
357
New
19
Increased
56
Reduced
184
Closed
64

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.7M
2
RDDT icon
Reddit
RDDT
+$31.5M
3
MTSI icon
MACOM Technology Solutions
MTSI
+$13.3M
4
FCFS icon
FirstCash
FCFS
+$10.8M
5
DKNG icon
DraftKings
DKNG
+$10.5M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$37.4M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$23.2M
3
AMZN icon
Amazon
AMZN
+$12.7M
4
CIEN icon
Ciena
CIEN
+$12.1M
5
CNM icon
Core & Main
CNM
+$11.8M

Sector Composition

Rank Sector Weight
1 Technology 28.22%
2 Healthcare 15.69%
3 Financials 15.15%
4 Consumer Discretionary 13.95%
5 Industrials 10.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYBR
101
DELISTED
CyberArk
CYBR
$9.12M 0.28%
20,442
-3,330
-14% -$1.6M
FLOC
102
Flowco Holdings
FLOC
$973M
$8.97M 0.28%
478,648
+66,482
+16% +$1.11M
GENI icon
103
Genius Sports
GENI
$2.16B
$8.92M 0.27%
809,234
-10,874
-1% -$119K
NCNO icon
104
nCino
NCNO
$2.1B
$8.8M 0.27%
343,051
+48,908
+17% +$1.24M
KNSA icon
105
Kiniksa Pharmaceuticals
KNSA
$6.07B
$8.7M 0.27%
210,910
-3,454
-2% -$139K
BLFS icon
106
BioLife Solutions
BLFS
$1.7B
$8.62M 0.26%
356,343
-4,799
-1% -$126K
ADMA icon
107
ADMA Biologics
ADMA
$2.22B
$8.6M 0.26%
471,456
-59,068
-11% -$996K
KNX icon
108
Knight Transportation
KNX
$11.2B
$8.56M 0.26%
163,800
-15,282
-9% -$716K
AXSM icon
109
Axsome Therapeutics
AXSM
$11.1B
$8.52M 0.26%
46,633
-17,888
-28% -$2.5M
DAVE icon
110
Dave Inc
DAVE
$3.95B
$8.46M 0.26%
+38,230
New +$8.22M
ASO icon
111
Academy Sports + Outdoors
ASO
$3.07B
$8.31M 0.25%
166,353
+17,052
+11% +$846K
RYAN icon
112
Ryan Specialty Holdings
RYAN
$10.8B
$8.24M 0.25%
159,501
-16,424
-9% -$901K
FOUR icon
113
Shift4
FOUR
$3.24B
$8.19M 0.25%
130,018
+11,024
+9% +$779K
NBIX icon
114
Neurocrine Biosciences
NBIX
$16.5B
$8.17M 0.25%
57,578
-1,266
-2% -$183K
CBLL
115
CeriBell Inc
CBLL
$809M
$7.96M 0.24%
363,059
-4,886
-1% -$75.8K
BRZE icon
116
Braze
BRZE
$3.18B
$7.94M 0.24%
231,517
-3,175
-1% -$94.1K
VITL icon
117
Vital Farms
VITL
$496M
$7.92M 0.24%
248,086
+54,192
+28% +$1.91M
XENE icon
118
Xenon Pharmaceuticals
XENE
$6.11B
$7.84M 0.24%
+174,851
New +$7.34M
PRVA icon
119
Privia Health
PRVA
$2.81B
$7.83M 0.24%
330,312
-4,247
-1% -$103K
GNRC icon
120
Generac Holdings
GNRC
$12.7B
$7.81M 0.24%
57,264
-1,280
-2% -$207K
FCN icon
121
FTI Consulting
FCN
$4.22B
$7.68M 0.24%
44,984
-618
-1% -$102K
BANC icon
122
Banc of California
BANC
$3.09B
$7.67M 0.24%
397,635
-19,673
-5% -$353K
ODD icon
123
ODDITY Tech
ODD
$576M
$7.65M 0.23%
190,485
+45,253
+31% +$2.05M
VSXY
124
Victoria's Secret
VSXY
$7.48B
$7.61M 0.23%
140,470
-75,225
-35% -$2.99M
SIBN icon
125
SI-BONE Inc
SIBN
$843M
$7.47M 0.23%
378,791
-4,991
-1% -$86.7K
3 4
5
6 7

Similar funds

CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
MRCP
Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
SAG
Susquehanna Advisors Group Bala Cynwyd, Pennsylvania $3.05B AUM 41.49% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Peregrine Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Peregrine Capital Management held 357 positions worth $3.26B, down 1.8% from $3.32B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Peregrine Capital Management's Q4 2025 filing shows 19 new, 56 increased, 184 reduced and 64 closed positions. Its largest new stake was Eli Lilly: 42,567 shares worth $45.7M. The largest sale was Exact Sciences, an estimated $37.4M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.

  • Peregrine Capital Management's largest Q4 2025 buy was Eli Lilly: 42,567 shares worth $45.7M.
  • Peregrine Capital Management added most to DraftKings in Q4 2025, an estimated $10.5M increase.
  • Peregrine Capital Management's biggest Q4 2025 reduction was Exact Sciences, cutting an estimated $37.4M.
  • Peregrine Capital Management fully exited Core & Main in Q4 2025, selling an estimated $11.8M.
  • Peregrine Capital Management's ten largest holdings make up 26% of its $3.26B portfolio in Q4 2025.
  • Peregrine Capital Management opened 19 new positions and closed 64 in Q4 2025.
  • Peregrine Capital Management's portfolio value fell 1.8% quarter-over-quarter to $3.26B.

Based on Peregrine Capital Management's 13F filing for Q4 2025, filed 28 Jan 2026.